News
Video
Author(s):
Zachariah DeFilipp, MD, presents data from AGAVE-201, a phase 2, open-label, randomized, multicenter study evaluating axatilimab at 3 dose levels in patients with recurrent/refractory chronic graft-versus-host disease (GVHD).
Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas
Amphiphile Lymph Node–Targeted Vaccine Is Safe and Bolsters T-Cell Responses in MRD+ PDAC and CRC
JNJ-6420 Elicits Responses in mCRPC, But Safety Concerns Arise
ARV-766 Demonstrates Clinical Activity in AR LBD–Mutated Metastatic CRPC